3-[1-(2-fluorophenyl)naphthalen-2-ylsulfanyl]propionic acid ethyl ester | 1264712-19-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-[1-(2-fluorophenyl)naphthalen-2-ylsulfanyl]propionic acid ethyl ester
• 英文别名: Ethyl 3-[1-(2-fluorophenyl)naphthalen-2-yl]sulfanylpropanoate
• CAS: 1264712-19-7
• 化学式: C₂₁H₁₉FO₂S
• 分子量: 354.445
• InChiKey: RSHHEEBRQOHEDR-UHFFFAOYSA-N

物化性质

• 熔点：
  75-76 °C(Solv: heptane (142-82-5))
• 沸点：
  474.9±40.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[1-(2-fluorophenyl)naphthalen-2-ylsulfanyl]propionic acid ethyl ester 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 以99%的产率得到苯并萘(1,2-D)噻唑
  参考文献：
  名称：

  功能化二苯并噻吩的合成 - 基于 Pd 催化 CC 和 CS 键形成的高效三步法

  摘要：

  提出了一种新颖有效的三步法，用于从常见的起始材料和使用钯催化的碳-碳和碳-硫键形成合成功能化二苯并噻吩 (DBT)。与先前报道的方法相比，反应条件提供了显着改善的官能团耐受性和区域选择性。

  DOI：

  10.1002/ejoc.201001393
• 作为产物：
  描述：

  2-[1-(2-fluoro-phenyl)naphthalen-2-yloxy]tetrahydropyran 在 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium carbonate 、 三乙胺 、 双(2-二苯基磷苯基)醚 作用下， 以 甲醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 17.0h， 生成 3-[1-(2-fluorophenyl)naphthalen-2-ylsulfanyl]propionic acid ethyl ester
  参考文献：
  名称：

  功能化二苯并噻吩的合成 - 基于 Pd 催化 CC 和 CS 键形成的高效三步法

  摘要：

  提出了一种新颖有效的三步法，用于从常见的起始材料和使用钯催化的碳-碳和碳-硫键形成合成功能化二苯并噻吩 (DBT)。与先前报道的方法相比，反应条件提供了显着改善的官能团耐受性和区域选择性。

  DOI：

  10.1002/ejoc.201001393

文献信息

• URAT1 INHIBITOR
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US20170290795A1

  公开（公告）日：2017-10-12

  Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia. (In the Formula (III), R 1a , R 2a , R 6a , and R 7a represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, or a cyano group, R 3a and R 8a form a benzene ring or a 5-membered heteroaryl ring containing 1 to 3 heteroatoms, as a ring constituent element, selected from nitrogen atoms, oxygen atoms, and sulfur atoms together with two carbon atoms to which R 3a and R 8a are bonded, R 4a and R 5a form a benzene ring together with two carbon atoms to which R 4a and R 5a are bonded or represent any of the groups represented by R 1a described above, W a represents CR 10a or N, and where, R 10a represents any of the groups represented by R 1a , X a represents an oxygen atom or a sulfur atom, Y a represents an alkylene chain having 1 to 8 carbon atoms, and where, the alkylene chain may be substituted with an alkyl group having 1 to 8 carbon atoms and the alkylene chain may be a linear or branched alkylene chain, the branched alkylene chain may have a 3- to 7-membered ring formed by side chains bonded to carbon atoms which are the same as or different from each other, together with the carbon atoms to which the side chains are bonded and may have a double bond in the middle thereof, and Z a represents CO 2 H.)

  提供的是以下公式（III）所代表的化合物，该化合物的互变异构体或立体异构体，或者是作为痛风或高尿酸血症治疗剂的药用可接受盐或溶剂。（在公式（III）中，R1a、R2a、R6a和R7a代表氢原子、具有1至8个碳原子的烷基、具有1至8个碳原子的烷氧基或氰基，R3a和R8a形成苯环或含有1至3个杂原子（从氮原子、氧原子和硫原子中选择）的5元杂环，作为环构成元素，与R3a和R8a结合的两个碳原子一起，R4a和R5a与R4a和R5a结合的两个碳原子一起形成苯环，或代表上述R1a描述的任何基团，W代表CR10a或N，其中R10a代表上述R1a描述的任何基团，X代表氧原子或硫原子，Y代表具有1至8个碳原子的烷基链，其中烷基链可能被具有1至8个碳原子的烷基取代，且烷基链可能是直链或支链烷基链，支链烷基链可能由连接到相同或不同的碳原子的侧链形成3至7个成员环，与侧链结合的碳原子以及可能在其中间具有双键，并且Z代表CO2H。）
• ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：EP3705120A1

  公开（公告）日：2020-09-09

  There is provided an activator of peroxisome proliferator-activated receptor α which contains: a compound represented by the following Formula (I); a tautomer or stereoisomer of the compound; or a pharmaceutically acceptable salt or solvate thereof (where, in a case where R1, R2, R3, and R8 do not constitute a ring, in the Formula, R1, R2, R3, R6, R7, and R8 may be the same as or different from each other and represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, an alkoxy group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, a hydroxy group, an amino group, a carboxyl group, a mercapto group, an alkylsulfanyl group having 1 to 8 carbon atoms, a nitro group, or a cyano group).

  本发明提供了一种过氧化物酶体增殖体激活受体 α 的激活剂，其中含有由下式(I)代表的化合物； 该化合物的同分异构体或立体异构体；或其药学上可接受的盐或溶液（其中，在 R1、R2、R3 和 R8 不构成环的情况下，在式中，R1、R2、R3、R6、R7 和 R8 可彼此相同或不同，并代表氢原子、卤素原子、具有 1 至 8 个碳原子的烷基、具有 1 至 8 个碳原子的烷氧基、被 1 至 3 个卤素原子取代的 1 至 8 个碳原子的烷基、被 1 至 3 个卤素原子取代的 1 至 8 个碳原子的烷氧基、羟基、氨基、羧基、巯基、1 至 8 个碳原子的烷硫基、硝基或氰基）。
• URAT1 inhibitor
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US10173990B2

  公开（公告）日：2019-01-08

  Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia. (In the Formula (III), R1a, R2a, R6a, and R7a represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, or a cyano group, R3a and R8a form a benzene ring or a 5-membered heteroaryl ring containing 1 to 3 heteroatoms, as a ring constituent element, selected from nitrogen atoms, oxygen atoms, and sulfur atoms together with two carbon atoms to which R3a and R8a are bonded, R4a and R5a form a benzene ring together with two carbon atoms to which R4a and R5a are bonded or represent any of the groups represented by R1a described above, Wa represents CR10a or N, and where, R10a represents any of the groups represented by R1a, Xa represents an oxygen atom or a sulfur atom, Ya represents an alkylene chain having 1 to 8 carbon atoms, and where, the alkylene chain may be substituted with an alkyl group having 1 to 8 carbon atoms and the alkylene chain may be a linear or branched alkylene chain, the branched alkylene chain may have a 3- to 7-membered ring formed by side chains bonded to carbon atoms which are the same as or different from each other, together with the carbon atoms to which the side chains are bonded and may have a double bond in the middle thereof, and Za represents CO2H).

  本发明提供了由下式（III）代表的化合物、该化合物的同分异构体或立体异构体或其药学上可接受的盐或溶液，用作痛风或高尿酸血症的治疗剂。(在式（III）中，R1a、R2a、R6a 和 R7a 代表氢原子、具有 1 至 8 个碳原子的烷基、具有 1 至 8 个碳原子的烷氧基或氰基，R3a 和 R8a 构成苯环或含有 1 至 3 个杂原子的 5 元杂芳基环，作为环组成元素、选自氮原子、氧原子和硫原子，与 R3a 和 R8a 键合的两个碳原子一起，R4a 和 R5a 与 R4a 和 R5a 键合的两个碳原子一起形成苯环，或代表上述 R1a 所代表的任何基团，Wa 代表 CR10a 或 N，其中、R10a 代表 R1a 所代表的任何基团，Xa 代表氧原子或硫原子，Ya 代表具有 1 至 8 个碳原子的亚烷基链，其中，亚烷基链可以被具有 1 至 8 个碳原子的烷基取代，亚烷基链可以是直链或支链亚烷基链、支链亚烷基链可具有一个 3 至 7 元环，该环由与彼此相同或不同的碳原子键合的侧链以及与侧链键合的碳原子形成，并可在其中间具有一个双键，Za 代表 CO2H）。
• Activator of peroxisome proliferator-activated receptor
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US11278528B2

  公开（公告）日：2022-03-22

  There is provided an activator of peroxisome proliferator-activated receptor α which contains: a compound represented by the following Formula (I); a tautomer or stereoisomer of the compound; or a pharmaceutically acceptable salt or solvate thereof (where, in a case where R1, R2, R3, and R8 do not constitute a ring, in the Formula, R1, R2, R3, R6, R7, and R8 may be the same as or different from each other and represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, an alkoxy group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, a hydroxy group, an amino group, a carboxyl group, a mercapto group, an alkylsulfanyl group having 1 to 8 carbon atoms, a nitro group, or a cyano group).

  本发明提供了一种过氧化物酶体增殖体激活受体 α 的激活剂，其中含有由下式(I)代表的化合物； 该化合物的同分异构体或立体异构体；或其药学上可接受的盐或溶液（其中，在 R1、R2、R3 和 R8 不构成环的情况下，在式中，R1、R2、R3、R6、R7 和 R8 可彼此相同或不同，并代表氢原子、卤素原子、具有 1 至 8 个碳原子的烷基、具有 1 至 8 个碳原子的烷氧基、被 1 至 3 个卤素原子取代的 1 至 8 个碳原子的烷基、被 1 至 3 个卤素原子取代的 1 至 8 个碳原子的烷氧基、羟基、氨基、羧基、巯基、1 至 8 个碳原子的烷硫基、硝基或氰基）。
• ACTIVATOR OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US20200268719A1

  公开（公告）日：2020-08-27

  There is provided an activator of peroxisome proliferator-activated receptor α which contains: a compound represented by the following Formula (I); a tautomer or stereoisomer of the compound; or a pharmaceutically acceptable salt or solvate thereof (where, in a case where R 1 , R 2 , R 3 , and R 8 do not constitute a ring, in the Formula, R 1 , R 2 , R 3 , R 6 , R 7 , and R 8 may be the same as or different from each other and represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, an alkoxy group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, a hydroxy group, an amino group, a carboxyl group, a mercapto group, an alkylsulfanyl group having 1 to 8 carbon atoms, a nitro group, or a cyano group).